Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 13138Neoplasms 10481Carcinoma, Non-Small-Cell Lung 6874Prostatic Neoplasms 6268Colorectal Neoplasms 5948Lung Neoplasms 5105Multiple Myeloma 3577Pancreatic Neoplasms 3563Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3508Carcinoma, Hepatocellular 3273Ovarian Neoplasms 3168Melanoma 3141Stomach Neoplasms 3057Lymphoma 2983Head and Neck Neoplasms 2604Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2313Lymphoma, Non-Hodgkin 2269Rectal Neoplasms 2192Uterine Cervical Neoplasms 2191Glioblastoma 2016Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1848Esophageal Neoplasms 1801

Interventions

mocetinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rubinstein-Taybi Syndrome × Clear all
NCT06740162 2026-02-23

PACE

University of North Carolina, Chapel Hill

Phase NA Recruiting
376 enrolled

Autism Spectrum Disorder, Trisomy 13 Syndrome, Cri-du-Chat Syndrome, De Lange Syndrome, Down Syndrome, Fragile X Syndrome, Intellectual Disability, Motor Activity, Prader-Willi Syndrome, Rubinstein-Taybi Syndrome, WAGR Syndrome, Williams Syndrome, X-Linked Intellectual Disability, Neurodevelopmental Disorders

NCT02236195 2017-09-01

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Mirati Therapeutics Inc.

Phase 2 Completed
17 enrolled
Genitourinary

Carcinoma, Transitional Cell, Rubinstein-Taybi Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡